Pilot Phase II Study of Metronomic Chemotherapy in Combination with Bevacizumab in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Highlights • Metronomic chemotherapy appears tolerable and effective treatment strategy. • Improved PFS and OS. • Plasma biomarkers could potentially prognosticate responders to MC treatment.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-04, Vol.106, p.125-130
Hauptverfasser:	Jones, Benjamin S, Jerome, Mary S, Miley, Deborah, Jackson, Bradford E, DeShazo, Mollie R, Reddy, Vishnu V.B, Singh, Karan P, Brown, Olivia C, Robert, Francisco
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Metronomic Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - pharmacology Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - therapeutic use Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - therapeutic use Bevacizumab Bevacizumab - administration & dosage Bevacizumab - pharmacology Biomarkers, Pharmacological - blood Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - drug therapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Disease-Free Survival Drug Therapy, Combination - methods Female Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - pathology Male Metronomic chemotherapy Middle Aged Neoplasm Staging Non-small cell lung cancer Paclitaxel - administration & dosage Paclitaxel - therapeutic use Pulmonary/Respiratory Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!